Reid Huber
About Reid Huber
Reid Huber is a Director at Rapport Therapeutics and Asher Biotherapeutics, with extensive experience in the biotechnology sector. He has held various leadership roles, including Partner at Third Rock Ventures and CEO at MOMA Therapeutics, contributing to the strategic development of multiple companies.
Current Roles at Rapport Therapeutics
Reid Huber serves as Director at Rapport Therapeutics, a position he has held since 2022. He is based in Boston, Massachusetts, where he contributes to the company's strategic initiatives and operational oversight. Huber's role involves guiding the development of therapeutic solutions within the organization.
Experience at Third Rock Ventures
Since 2018, Reid Huber has been a Partner at Third Rock Ventures in Boston, MA. In this capacity, he has played a significant role in the formation and strategic development of the firm's portfolio companies. His expertise in the biotechnology sector supports the growth and innovation of emerging companies.
Education and Academic Background
Reid Huber earned his PhD in Molecular Genetics and Biochemistry from Washington University School of Medicine in St. Louis, where he studied from 1994 to 1998. He also holds a Bachelor of Science degree in Molecular Genetics and Biochemistry from Murray State University, completed from 1991 to 1994.
Previous Leadership at MOMA Therapeutics
Reid Huber previously held the position of CEO at MOMA Therapeutics from 2020 to 2021. During his tenure, he was instrumental in guiding the company's strategic direction and operational framework. He also currently serves as a Director at MOMA Therapeutics, a role he has maintained since 2020.
Scientific Contributions and Research Experience
Reid Huber has a robust background in scientific research, having held positions at DuPont and Bristol-Myers Squibb from 1998 to 2002. He was also a member of the founding scientific team at Incyte, where he contributed to the company's early scientific direction and later served as Senior Vice President of Discovery Biology starting in 2011.